Bradley Canino
Stock Analyst at Guggenheim
(4.33)
# 1,336
Out of 5,023 analysts
291
Total ratings
45.8%
Success rate
10.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DMRA Damora Therapeutics | Maintained: Buy | $40 → $60 | $20.25 | +196.30% | 6 | Sep 25, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $70 | $29.05 | +140.96% | 1 | Sep 15, 2026 | |
| KYMR Kymera Therapeutics | Rated: Buy | $135 → $170 | $115.81 | +46.79% | 22 | Aug 30, 2026 | |
| CELC Celcuity | Rated: Buy | $165 → $175 | $79.37 | +120.49% | 16 | Aug 16, 2026 | |
| JANX Janux Therapeutics | Rated: Buy | $58 → $55 | $16.68 | +229.74% | 10 | Aug 6, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $13.18 | +36.57% | 11 | Aug 3, 2026 | |
| SMMT Summit Therapeutics | Rated: Buy | $40 → $38 | $16.38 | +131.99% | 16 | Jul 23, 2026 | |
| ANTX AN2 Therapeutics | Initiated Coverage: Buy | $9 | $4.89 | +84.05% | 1 | Jul 19, 2026 | |
| SNDX Syndax Pharmaceuticals | Reiterated: Buy | $31 | $17.97 | +72.51% | 18 | Jul 14, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $38 → $35 | $9.04 | +287.17% | 5 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $19.78 | +112.34% | 2 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 → $26 | $17.73 | +46.64% | 18 | May 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $14.23 | +145.92% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $22.41 | +140.96% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $15.44 | +94.30% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $68.76 | +30.89% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $7 | $3.03 | +131.02% | 20 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.89 | - | 17 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $10.86 | n/a | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $5 | $2.92 | n/a | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $2.75 | n/a | 23 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $1.5 | $1.36 | n/a | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $63 → $51 | $7.79 | n/a | 25 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 13 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $4.66 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $3.80 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $13.41 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $48.61 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $57.95 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $26.81 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 | $23.66 | n/a | 1 | Jul 8, 2020 |
Damora Therapeutics
Sep 25, 2026
Maintained: Buy
Price Target: $40 → $60
Current: $20.25
Upside: +196.30%
Faeth Therapeutics
Sep 15, 2026
Initiated Coverage: Buy
Price Target: $70
Current: $29.05
Upside: +140.96%
Kymera Therapeutics
Aug 30, 2026
Rated: Buy
Price Target: $135 → $170
Current: $115.81
Upside: +46.79%
Celcuity
Aug 16, 2026
Rated: Buy
Price Target: $165 → $175
Current: $79.37
Upside: +120.49%
Janux Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $58 → $55
Current: $16.68
Upside: +229.74%
ORIC Pharmaceuticals
Aug 3, 2026
Reiterated: Buy
Price Target: $18
Current: $13.18
Upside: +36.57%
Summit Therapeutics
Jul 23, 2026
Rated: Buy
Price Target: $40 → $38
Current: $16.38
Upside: +131.99%
AN2 Therapeutics
Jul 19, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $4.89
Upside: +84.05%
Syndax Pharmaceuticals
Jul 14, 2026
Reiterated: Buy
Price Target: $31
Current: $17.97
Upside: +72.51%
Olema Pharmaceuticals
Jun 1, 2026
Reiterated: Buy
Price Target: $38 → $35
Current: $9.04
Upside: +287.17%
May 26, 2026
Reiterated: Buy
Price Target: $42
Current: $19.78
Upside: +112.34%
May 25, 2026
Reiterated: Buy
Price Target: $22 → $26
Current: $17.73
Upside: +46.64%
Apr 29, 2026
Reiterated: Buy
Price Target: $35
Current: $14.23
Upside: +145.92%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $22.41
Upside: +140.96%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $15.44
Upside: +94.30%
Feb 27, 2026
Reiterated: Buy
Price Target: $90
Current: $68.76
Upside: +30.89%
Feb 26, 2026
Reiterated: Buy
Price Target: $8 → $7
Current: $3.03
Upside: +131.02%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.89
Upside: -
Sep 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $10.86
Upside: n/a
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $10 → $5
Current: $2.92
Upside: n/a
Mar 27, 2025
Reiterated: Buy
Price Target: $9
Current: $2.75
Upside: n/a
Mar 7, 2025
Reiterated: Hold
Price Target: $3 → $1.5
Current: $1.36
Upside: n/a
Feb 12, 2025
Reiterated: Buy
Price Target: $63 → $51
Current: $7.79
Upside: n/a
Jan 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $4.66
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $37
Current: $3.80
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $15
Current: $13.41
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $65
Current: $48.61
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $57.95
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $55
Current: $26.81
Upside: n/a
Jul 8, 2020
Initiated Coverage: Buy
Price Target: $38
Current: $23.66
Upside: n/a